In a recent study, DCs were genetically engineered to co-express an anti-CD19 scFv and PD1, producing bispecific EVs (bisEVs), capable of simultaneously targeting tumor antigens and blocking PD-L1, thereby reshaping the immune environment within solid tumors. This evidence concerns the gene PDCD1 and neoplasm.